Welcome to our dedicated page for Autolus Therapeutics plc American Depositary Share news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics plc American Depositary Share stock.
Autolus Therapeutics plc (NASDAQ: AUTL) is a pioneering biopharmaceutical company dedicated to the development and commercialization of engineered T-cell immunotherapy products. These innovative therapies are designed to treat life-threatening cancers with remarkable efficacy. Autolus is at the forefront of biotechnology, focusing on both haematological and solid tumors using patient-specific T-cell therapies.
At the heart of Autolus' clinical-stage pipeline is obecabtagene autoleucel (obe-cel). Additional promising candidates include AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. These products represent the next generation of programmed T-cell therapies, offering new hope for cancer patients worldwide.
Autolus' strategic initiatives are equally impressive. The company has formed a strategic alliance with BioNTech SE, a key player in the biotech industry. This partnership is poised to enhance the development and reach of Autolus' therapies. Additionally, Autolus has successfully completed an underwritten offering, strengthening its financial foundation.
Recent financial results highlight the company's strong performance. For the full year ended December 31, 2023, Autolus reported unaudited financial results, including significant UK SME R&D Tax Credits. These credits amounted to $19.5 million and $24.6 million for the years ended December 31, 2023, and 2022, respectively, providing a substantial boost to their research and development efforts.
Looking ahead, Autolus has outlined key updates and anticipated milestones for obe-cel, along with financial results for the quarter ended March 31, 2024. These updates are critical for investors and stakeholders who are keen to track the company's progress and achievements.
In summary, Autolus Therapeutics plc is leading a transformative revolution in medicine, treating life-threatening diseases through cutting-edge T-cell therapies. The company's strategic partnerships, robust pipeline, and solid financials position it as a leader in the biopharmaceutical industry.
Engitix has successfully closed a
Autolus Therapeutics plc (Nasdaq: AUTL) announces the retirement of CFO Andrew J. Oakley on March 31, 2022, transitioning to a non-executive director role while remaining an advisor until March 2023. Dr. Lucinda Crabtree, currently SVP of Finance, will succeed him. Oakley highlighted the company's strong financial position following a deal with Blackstone Life Sciences, allowing for strategic advancement of its lead candidate, obe-cel. Crabtree brings extensive financial experience and previously oversaw major public offerings for Autolus.
Autolus Therapeutics (AUTL) announces its 2022 corporate priorities, emphasizing the pivotal developments of its candidate obe-cel for adult ALL patients. The Phase 2 FELIX study anticipates data mid-2022, with patient recruitment ongoing. Management highlights the favorable safety profile from the Phase 1b portion of the trial, with no severe cytokine release syndrome noted. Additionally, financial backing of up to $250 million from Blackstone Life Sciences will aid in advancing therapeutic initiatives, including its new manufacturing facility in the UK to enhance production capabilities.
Autolus Therapeutics (Nasdaq: AUTL) announced its participation in two upcoming virtual conferences: the H.C. Wainwright BioConnect Conference on January 10, 2022, featuring Dr. Lucinda Crabtree, and the J.P. Morgan Healthcare Conference on January 12, 2022, with Dr. Christian Itin presenting. Both events will include investor meetings and will be accessible via Autolus' website, where an archived replay will be available for 90 days. Autolus is known for developing next-generation T cell therapies targeting cancer.
Autolus Therapeutics (AUTL) provided updates on its CAR T therapy, obe-cel, at the ASH 2021 Annual Meeting. The ALLCAR19 study reported a morphological event-free survival (EFS) of 46% at 24 months. Obe-cel achieved a metabolic complete response in 100% of patients with follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma, showing favorable safety with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported. The company anticipates further clinical data in 2022.
Autolus Therapeutics (Nasdaq: AUTL) will hold a conference call on December 13, 2021, at 8:00 am ET to discuss data presented at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place December 11-14. This call reflects a timing change from the previous announcement. The call will include a webcast with accompanying slides available on the company's website. A replay of the call will be accessible for one week after.
Autolus Therapeutics plc (Nasdaq: AUTL) announced the appointment of Dr. William D. Young as a non-executive director, effective immediately. This decision follows a recent investment by Blackstone Life Sciences. Dr. Young brings over 50 years of experience in the life sciences sector, previously serving as COO of Genentech and CEO of Monogram Biosciences. His expertise is expected to enhance the commercial strategy of the company’s investigational therapy, Obe-cel, which aims to improve outcomes for adult patients with acute lymphoblastic leukemia and other cancers.
Autolus Therapeutics has published a significant article in Nature Scientific Reports detailing its controllable CAR T cell system, named TetCAR. This innovative approach allows for reversible dampening of programmed T cell activity using widely available antibiotics, tetracycline and minocycline. Such control mechanisms are crucial for managing severe adverse side effects in patients undergoing CAR T cell therapy. The company emphasizes that this method is based on established pharmacological agents, enhancing its practical application in clinical settings.
Autolus Therapeutics has announced a strategic collaboration with Blackstone Life Sciences, securing up to $250 million in financing to advance its investigational therapy, obe-cel, for adult acute lymphoblastic leukemia (ALL). The investment includes $150 million in product financing, with $50 million available at closing. Blackstone will also acquire $100 million in Autolus' American Depositary Shares. This funding aims to support clinical development and initial commercialization activities for obe-cel, which has shown potential as a curative treatment in a last-line setting.
Autolus Therapeutics plc (Nasdaq: AUTL) announced progress in its CAR T cell therapies, specifically obe-cel (AUTO1), at the 63rd ASH Annual Meeting in December 2021. The company will present an oral session on the industrialization of its Miltenyi Prodigy-Based manufacturing process and poster presentations on its AUTO1 programs for adult and pediatric Acute Lymphocytic Leukemia. A conference call is scheduled for December 14, 2021, to discuss ASH data. Autolus aims to enhance safety and efficacy through its innovative therapies designed to target cancer cells effectively.
FAQ
What is the current stock price of Autolus Therapeutics plc American Depositary Share (AUTL)?
What is the market cap of Autolus Therapeutics plc American Depositary Share (AUTL)?
What does Autolus Therapeutics plc do?
What are the key products in Autolus' pipeline?
Who are Autolus' strategic partners?
What are the financial highlights for Autolus?
What recent milestones has Autolus achieved?
What are the anticipated milestones for obe-cel?
What is the significance of Autolus' therapies?
How does Autolus' financial condition support its research?
Where is Autolus Therapeutics plc listed?
What is the mission of Autolus Therapeutics plc?
